Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Chinese and Japanese Male Volunteers (Randomised, Single-blind, Placebo-controlled Trial)
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2018
At a glance
- Drugs BI 685509 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Jun 2018 Status changed from active, no longer recruiting to completed.
- 29 May 2018 Planned End Date changed from 30 Jun 2018 to 26 May 2018.
- 29 May 2018 Planned primary completion date changed from 31 May 2018 to 26 May 2018.